Matthew W. Foehr's holdings in Ligand Pharmaceuticals reflect his dedication to the company. In recent years, he has primarily held shares without significant fluctuations, indicating a stable investment in the biotechnology sector. His peaks in wealth tied to his holdings...

Matthew W. Foehr's holdings in Ligand Pharmaceuticals reflect his dedication to the company. In recent years, he has primarily held shares without significant fluctuations, indicating a stable investment in the biotechnology sector. His peaks in wealth tied to his holdings were around 2018 when he received substantial stock awards valued over $2.7 million during a period of increased company growth and performance. Currently, while he is not reported to have large stock grants or options, his previous awards have demonstrated a commitment to tying his personal success to the company's progress.